Morepen Laboratories achieved its best quarterly results to date in Q1 FY27. The firm saw a 34% year-on-year revenue increase to ₹575.31 crore, while profit after tax (PAT) skyrocketed by 394% to reach ₹56.35 crore. Additionally, the company has started work on its ₹825 crore CDMO contract. A 42% growth in API exports further fueled the momentum, pushing the company's shares to the 20% upper circuit.
by shortkt.com✓